Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
New Orleans health officials say state'level reclassification of mifepristone and misoprostol has reduced access and should be repealed
Summary
The New Orleans Health Department reported that a 2024 Louisiana law reclassifying mifepristone and misoprostol as Schedule IV drugs has produced pharmacy stockouts, delays in inpatient and outpatient care and patient harm; the department recommended repeal and statewide monitoring.
The New Orleans Health Department presented findings to the City Council on a year-long evaluation of the 2024 law that reclassified mifepristone and misoprostol as Schedule IV controlled substances, saying the change has reduced pharmacy availability and delayed urgent care.
The department'wide evaluation, introduced by Director Jennifer Avegno, MD, and briefed by Deputy Jeannie Donovan and analysts, found that only about half of pharmacies in Orleans and Jefferson parishes stock misoprostol and that stocking and dispensing declined after the law took effect on Oct. 1, 2024. The department said delays affected inpatient emergency care, postpartum hemorrhage treatment and outpatient management of miscarriage and other…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
